FDA advisory panels

Each agent has been classified as safe and effective by an FDA advisory panel. Some combinations may be synergistic (e.g., sulfur and resorcinol). 

The Council supports the recommendations of the USP-FDA Advisory Panel on Simplification of Injection Labeling. Furthermore, the Council encourages USP/FDA to consider expansion of the concepts of simplification to apply to package inserts and... 

The reports were sent to the FDA through its postmarketing spontaneous reporting system (SRS). The FDA representative projected the data onto a screen, but the data were not included in the transcript of the meeting. Although this issue was of overriding, central importance to its deliberations, the FDA advisory panel made no response at all to it. It was as if the data, so critical to their conclusions, had been presented to an empty room. 

The defining structural element found in rolipram and its relatives is the dialkoxyphenyl (catechol) moiety. Although the development of rolipram (then for depression) was terminated early, many companies have since disclosed PDE4 inhibitors intended primarily for indications such as asthma and COPD (chronic obstructive pulmonary disease) [58], For a long time, cilomilast (Ariflo, 54) has appeared to be ahead in this race [59], In November 2003, GSK received an approvable letter from the FDA, despite the FDA advisory panel s earlier negative opinion of the compound. The extent to which new studies may have been requested by the FDA and will delay approval remains to be seen. 

Fox, J.L. (1993). FDA advisory panel okays beta interferon for MS. Bio/Technology 11,538 539. (Should be added to Table 1.3, bringing the total number to 20.)... 

Unless the device meets the criteria for a me too product, panel review will be required. Section 512(c)(2) of the act requires that a premarket approval application be referred to an appropriate FDA Advisory Panel for study and for submission of a report and recommendation respecting approval of the application. The definition of a me too device can be found in FDA Guidance P86-6, 7/25/86. 

Drug Formulations On September 10, 2013, the Food and Drug Agency (FDA) approved a novel oral extended release hydrocodone formulation, hydrocodone bitartrate (Zohydro ER) [39 ]. Interestingly, the FDA advisory panel earlier in 2013 had voted 11-2 against approval of Zohydro, but despite this recommendation, Zohydro was approved and is available in the United States. Zohydro is an oral capsule available in 10,15,20,30,40 and 50-mg... 

FDA Advisory Panel unanimously reconunends approval of Renova for photoaging... 

Horn omen thyl saUcylate (homosalate), employed as a sunscreen agent, is on a Hst of 21 compounds for OTC sunscreen products, recommended by the FDA advisory review panel on OTC bum and sunburn prevention as both "safe and effective" (30). Menthyl saUcylate (6) is also a sunscreen agent. 

As in Europe, the classification of devices plays a central role in the regulation of devices in the US. However, there are a number of differences compared to the European approach. First of all, responsibility for classification rests with the FDA rather than with the manufacturers. When the regulations were introduced, the FDA mandated expert advisory panels (classification panels) to consider the different types of device that existed on the market at that time. The FDA provided classification questionnaires to act as guidelines for the panels when assessing the devices. In determining the safety and effectiveness of a device for purposes of classification, the classification panels had to consider the intended user (not part of EU criteria), the... 

In 1992, the FDA issued a moratorium on silicone-gel-filled implants, and restricted their use to reconstmction and clinical smdies. In 2000, they approved saline-filled implants. In 2003, the General and Plastic Surgery Devices (GPSD) Advisory Panel recommended reapproval of gel-filled implants, but the FDA decided to wait for more clinical evidence of safety. In late 2005, the Panel recommended conditional approval of Mentor s and Inamed s gel implants. In October 2006, Health Canada approved the use of sUicone-gel-filled implants, with a warning that no medical device is 100% safe. ... 

On January 23,2006, a scientific advisory panel to the Food and Drug Administration, FDA, in the United States recommended that a weight-loss drug previously available by prescription only be approved for sale over the counter (OTC). The drug in question is known by the generic name orlistat and it has been marketed in the United States by Hoffmann-La Roche since 1999 as Xenical. The OTC product is known as Alii and is marketed by GlaxoSmithKline. 

The FDA removed saccharin from its list of approved food additives in 1972, after it caused bladder tumors in rats. The rats were fed a daily amount of saccharin equivalent to the amount in 875 bottles of diet soda (Schmeck 1972). In late 1997, the scientific advisory panel to the National Toxicology Program (NTP) considered removing saccharin from the NTP s list of suspected carcinogens at the request of NTP scientists but voted 4 to 3 to leave saccharin on the list (Stolberg 1997). 

In 1972 the Federal Drug Administration (FDA) initiated an OTC drug study. The final report of seventeen advisory panels was issued in 1983. Only one-third of the 700 active ingredients in some 300.000 OTC products were found to be effective. Then in November 1990 the FDA banned 223 drugs found in OTCs because their therapeutic claims were unsubstantiated. All of the products affected had been in use since before 1962. 

Schwartz, J. (1994a, June 3). Researchers cleared in drug trial deaths NIH advisory panel s report on hepatitis studies at odds with findings by FDA. The Washington Post, p. A10. 

The Federal Register advance notice is a preliminary notice, offering opportunity for comment and submission of new data for consideration. When all comments have been collected and evaluated, the FDA publishes a rule, also termed a tentative final monograph. This publication incorporates all changes that were made on the basis of the results of the first publication. There is a review of comments made and a summary of the basis for decisions regarding these comments. That is, the FDA prints a review of the nature of the comments or objections that were filed in response to the first notice and is obligated to respond to these comments. This should be carefully studied, because it reflects both the scientific viewpoint of the advisory panel and the FDA policy decisions. 

In June 2001, a government advisory panel convened by the FDA concluded that GHB could be useful as a treatment for cataplexy, a rare but dangerous complication of the sleep disorder narcolepsy. This panel was asked to consider whether prescription sales should be permitted for GHB under the brand name Xyrem . The committee concluded that the manufacturer of the drug (Orphan Medical) had shown that Xyrem is useful in treating cataplexy, a complication that can cause people to collapse suddenly when their muscles lose strength. 

Orphan Medical received an FDA approval letter in July 2001. The advisory panel urged that if the FDA approved the drug, it should develop a strong risk management plan to... 

FDA ADVISORY COMMITTEE ON PROTOCOLS FOR SAFETY EVALUATION PANEL ON... 

A new admission policy addresses botanicals used as dietary supplements recommended for their official adoption by the USP Committee of Revision. When the FDA has approved a use or a USP DID advisory panel has accepted a use, it is to the USP. If neither condition is met, and there is no safety concern, the article is admitted into the NF. If there is a safety concern for an article, then no NF monograph is published, and USP DID will publish a monograph that... 

---